CTLA4 and neoplasm: P407-hydrogel-based CTLA4 therapy resulted in equal tumor growth inhibition efficiency in both tumor models as the “free” CTLA4 blockade treatment, which is consistent with our previous in vitro data (Supplementary Fig. 6) and our previous statement [26].